Articles tagged "Co-stimulation"

2019 American Transplant Congress
Belatacept Based Simultaneous Calcineurin Inhibitor Avoidance/Early Corticosteroid Withdrawal is Associated with Low New Onset Diabetes Risk
A. R. Shields¹, P. West-Thielke², E. S. Woodle¹, D. B. Kaufman³, J. Lipscomb⁴, J. P. Leone⁵, A. Wiseman⁶, E. King⁴, A. J. Matas⁷, R. R. Alloway for the BEST Study Group⁴
¹Transplant Surgery, U of Cincinnati, Cincinnati, OH, ²UIC, Chicago, IL, ³Transplant Surgery, U of Wisconsin, Madison, WI, ⁴U of Cincinnati, Cincinnati, OH, ⁵Tampa General, Tampa, FL, ⁶U of Colorado, Denver, CO, ⁷U Minnesota, Minneapolis, MN
*Purpose: Calcineurin inhibitor (CNI) and/or corticosteroid (CCS) therapy are associated with significant risk of new onset diabetes after transplantation (NODAT). An important consideration for simultaneous…
2019 American Transplant Congress
CNI-Free Therapy with Iscalimab (anti-CD40 mAb) Preserves Allograft Histology Compared to Standard of Care after Kidney Transplantation
E. Farkash¹, A. Naik¹, H. Tedesco-Silva², B. Nashan³, O. Witzke⁴, M. van den Hoogen⁵, S. Berger⁶, D. M. Cibrik⁷, S. Mulgaonkar⁸, D. B. Leeser⁹, R. Alloway¹⁰, A. Patel¹¹, J. Pratchke¹², C. Sommerer¹³, A. Wiseman¹⁴, A. Van Zuilen¹⁵, U. Laessing¹⁶, J. Rush¹⁶, B. Haraldsson¹⁶
¹Univ of Michigan, Ann Arbor, MI, ²Hospital do Rim, São Paulo, Brazil, ³Univ. Hamburg, Hamburg, Germany, ⁴Univ Essen, Essen, Germany, ⁵Erasmus MC, Rotterdam, Netherlands, ⁶UMC Groningen, Gröningen, Netherlands, ⁷Univ of Kansas, Kansas City, KS, ⁸Saint Barnabas MC, Livingston, NJ, ⁹East Carolina Univ, Greenville, NC, ¹⁰Univ of Cincinnati, Cincinnati, OH, ¹¹Henry Ford Hosp, Detroit, MI, ¹²Charité Univ, Berlin, Germany, ¹³Univ Heidelberg, Heidelberg, Germany, ¹⁴Univ of Colorado SM, Denver, CO, ¹⁵Univ MC, Utrecht, Netherlands, ¹⁶Novartis, Basel, Switzerland
*Purpose: To assess if calcineurin (CNI)-free therapy with iscalimab preserves the quality of transplanted kidney grafts.*Methods: Iscalimab (CFZ533) is a new, fully human, Fc-silenced, non-depleting,…
2019 American Transplant Congress
Early T Cell Infiltration is Modulated by PD-1/PD-L1 Interactions in Kidney Graft
Y. Shim, R. Fan, N. Dvorina, W. Baldwin
Inflammation and Immunity, Lerner Research Institute, Cleveland, OH
*Purpose: Allogeneic transplants elicit dynamic T cell responses that are modulated by positive and negative co-stimulatory receptors. We have investigated the impact of PD-1, a…
2019 American Transplant Congress
The mIR17-92 Cluster Promotes Costimulation Resistant Effector Memory T Cell-Mediated Alloresponses
H. Xu¹, Q. Guo¹, M. Song¹, A. Miler¹, Q. Li², A. Kirk¹
¹Surgery, Duke University, Durham, NC, ²Immunology, Duke University, Durham, NC
*Purpose: CD57 expression has been shown to identify a subset of memory T cells that are resistant to CD28/B7 costimulation blockade (B7CoB). This study was…
2019 American Transplant Congress
Dual Treatment of CD40 Silencing or Mesenchymal Stem Cells Infusion with Sub-Therapeutic Doses of Cyclosporine Effectively Prevents Acute Rejection in an Allogenic Model of Renal Transplantation
J. Guiteras¹, L. De Ramon¹, N. Bolaños¹, M. Franquesa², M. Gomà³, J. Cruzado⁴, N. Lloberas¹, J. Grinyó⁴, J. Torras⁴
¹IDIBELL, Hospitalet de Llobregat, Spain, ²IGTP, Badalona, Spain, ³Bellvitge Hospital, Hospitalet de Llobregat, Spain, ⁴Bellvitge Hospital / IDIBELL, Hospitalet de Llobregat, Spain
*Purpose: This study was designed to investigate the combination of CD40 silencing or MSC infusion with suboptimal doses of Cyclosporine in this renal allograft model.*Methods:…
2019 American Transplant Congress
The Important Roles of Dendritic Cells in Transplantation
T. Ueno¹, M. M. McGrath¹, M. Y. Yeung¹, S. Cai¹, Y. Ueno¹, T. Yokoyama², Y. Kihara², O. Konno², Y. Nakamura², H. Iwamoto², A. K. Chandraker¹
¹Medicine, Renal Division, Brigham and Women's Hospital, Transplantation Research Center, Boston, MA, ²Kidney Transplantation Surgery, Tokyo Medical University, Hachioji Medical Center, Tokyo, Japan
*Purpose: The interplay between dendritic cells (DCs) and T cells plays a central role in the process of allograft rejection. Upon antigen exposure, positive costimulatory…
2019 American Transplant Congress
Belatacept Based CNI Free Immunosuppression in Pancreas Transplantation. Results at 4 Years
J. Chen, J. Fridell, M. Yaqub, T. Taber, D. MIshler, O. Adebiyi, M. Mujtaba, A. Sharfuddin
Indiana University School of Medicine, Indianapolis, IN
*Purpose: CNI based Immunosuppression is a well known risk factor for worsening renal function. We report our experience in converting Pancreas Transplant recipients from tacrolimus…
2019 American Transplant Congress
Regulatory T Cells Combined with Costimulation Blockade Prevent Rejection of Vascularized Composite Allografts
B. Oh¹, G. Furtmüller¹, M. Grzelak¹, L. Vuong², M. Iglesias¹, M. Fryer³, D. Cooney¹, R. Chen⁴, Y. Guo⁵, W. Lee¹, G. Raimondi¹, G. Brandacher¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Washington University in St. Louis School of Medicine, St. Louis, MO, ³The University of Massachusetts Medical School, Worcester, MA, ⁴Kaohsiung Medical Univerity Hospital, Kaohsiung, Taiwan, ⁵Kaohsiung Medical University Hospital, Kaohsiung, Taiwan
*Purpose: Reconstructive transplantation represents a valid therapeutic option after devastating tissue loss. Routine clinical application, however, is hampered by the toxicity of long-term maintenance immunosuppression.…
2019 American Transplant Congress
Costimulatory Blockade and Allo-Specific Treg Therapy for Liver Transplant Recipients: Preclinical Data
L. Contreras-Ruiz¹, K. Shimozawa², R. Zhang¹, L. Turka³, J. F. Markmann³, E. C. Guinan²
¹Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, ²Radiation Oncology, Dana-Farber Cancer Institute, Boston, MA, ³Center of Transplantation Sciences, Massachussetts General Hosp., Boston, MA
*Purpose: Adoptive transfer of ex vivo generated donor-specific regulatory T cells (Treg) by using CD28/B7 costimulatory blockade (CSB) to induce transplant (TX) tolerance and minimize…
2019 American Transplant Congress
Impact Of Selective Cd28 Blockade On Protective Immunity To A Murine Epstein-Barr Virus Homolog
R. L. Crepeau, J. A. Elengickal, M. L. Ford
Surgery, Emory University, ATLANTA, GA
*Purpose: CTLA-4Ig blocks CD80/CD86, the ligands for both CD28 and CTLA-4. Thus, in addition to the intended effect of blocking CD28-mediated costimulation, CTLA4-Ig also has…